Table 4.
Association between UDP-glucuronosyltransferase1A1 genotypes and pharmacokinetics parameters
| Genotype | AUC CPT-11 | AUC SN-38 | AUC SN-38G | AUC SN-38G/AUC SN-38 ratio | ||||
| Median | P value | Median | P value | Median | P value | Median | P value | |
| UGT1A1*28 | ||||||||
| TA6/6 | 5554.57 | 0.1631 | 176.40 | 0.1491 | 582.14 | 0.9881 | 3.178 | 0.1581 |
| TA6/7 | 6919.11 | 213.25 | 591.86 | 3.330 | ||||
| TA7/7 | 9049.03 | 390.00 | 584.63 | 1.488 | ||||
| UGT1A1*6 | ||||||||
| G/G | 5811.73 | 0.9532 | 189.62 | 0.3202 | 529.96 | 0.2342 | 2.924 | 0.5912 |
| G/A | 6582.17 | 231.50 | 679.17 | 3.759 | ||||
| UGT1A1*28+*6 | ||||||||
| TA6/6 + G/G | 5297.41 | 0.2821 | 169.62 | 0.0841 | 529.96 | 0.3861 | 2.924 | 0.1881 |
| TA6/7 + G/G, TA6/6 + G/A | 6649.50 | 217.87 | 679.17 | 3.680 | ||||
| TA7/7 + G/G TA6/7+ G/A | 6213.46 | 297.89 | 584.63 | 1.488 | ||||
| UGT1A1*28 | ||||||||
| TA6/6, TA6/7 | 6030.13 | 0.8842 | 191.92 | 0.0672 | 582.14 | 1.0002 | 3.177 | 0.0572 |
| TA7/7 | 9049.03 | 390.00 | 584.63 | 1.488 | ||||
| UGT1A1*28+*6 | ||||||||
| TA6/6 + G/G, TA6/7 + G/G, TA6/6 + G/A | 6030.13 | 0.7482 | 183.37 | 0.0612 | 582.14 | 0.9152 | 3.177 | 0.0782 |
| TA7/7 + G/G, TA6/7 + G/A | 6213.46 | 297.89 | 584.63 | 1.488 | ||||
1
Kruskal-Wallis test;
2
Mann-Whitney U test. 34 patients were assessable for pharmacokinetics parameters. CPT-11: Irinotecan; UGT1A1: UDP-glucuronosyltransferase1A1; AUC: Area under concentration curve.